Walleye Capital
CCCC icon

Walleye Capital’s C4 Therapeutics CCCC Stock Holding History

Walleye Capital’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300
Closed -$573 – 4449
2025
Q4 		$573 Buy
+300
New +$711 ﹤0.01% 4399
2024
Q2 		– Sell
-14,900
Closed -$122K – 5625
2024
Q1 		$122K Buy
+14,900
New +$115K ﹤0.01% 4282

Other funds holding CCCC

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Walleye Capital's CCCC Position: Q1 2026 in Review

Walleye Capital reduced its C4 Therapeutics (CCCC) stake by 46% in Q1 2026, selling an estimated $481K and leaving 239,118 shares worth $629K. The position accounts for ﹤0.01% of the portfolio, ranked #2478.

Walleye Capital first reported a position in CCCC in Q4 2021 and has held it in 10 quarters since. The position peaked at $2.63M in Q4 2021. 123 funds tracked by Wall St. Rank hold CCCC as of Q1 2026.

  • Walleye Capital held 239,118 shares of C4 Therapeutics worth $629K as of Q1 2026.
  • Walleye Capital sold 204,223 C4 Therapeutics shares in Q1 2026, an estimated $481K.
  • C4 Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2478 holding.
  • Walleye Capital first reported a position in C4 Therapeutics in Q4 2021 and has held it in 10 quarters since.
  • Walleye Capital's C4 Therapeutics position peaked at $2.63M in Q4 2021.
  • 123 funds tracked by Wall St. Rank held C4 Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.